High-Dose Cytosine Arabinoside in the Treatment of Acute Lymphoblastic Leukaemia
“High-dose” cytosine arabinoside (HD-ara-C) was introduced into the management of acute lymphoblastic leukaemia (ALL) in adults at St. Bartholomew’s Hospital (SBH), London, Ospedali Riuniti, Bergamo and Ospedale San Bortolo, Vicenza in 1981. Prior to this time, a strategy of remission induction and consolidation with adriamycin, vincristine prednisolone and L-asparaginase (OPAL) [1,2], with subsequent dose escalation and addition of cyclophosphamide (HEAV’D) [2,3], followed by cranial irradiation and maintenance chemotherapy, left much room for improvement. Analysis of the prognostic significance of pretreatment variables made it possible to assign patients to either “low-risk” (cALLa positive, blast count < 10 × 109/I) or “high-risk” (the rest) categories .
KeywordstoxIcity Lymphoma Leukemia Oncol Cyclophosphamide
Unable to display preview. Download preview PDF.
- 3.Bassan R, Battista R, Rohatiner AZS et al. (1992) Treatment of adult acute lymphoblastic (ALL) over a 16 year period. Leukaemia 6(2): 186Google Scholar
- 8.Rohatiner AZS, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA (1984) High dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin’s lymphoma. Cancer Chemo Pharmacol 12: 90Google Scholar
- 9.Barnett M, Rohatiner AZS, Ganesan TS et al. (1987) A phase II study of high-dose Cytosine arabinoside in the treatment of acute leukaemia in adults. Cancer Chemo Pharmacol 19: 169–171Google Scholar
- 12.Sallan S et al. (1991) BloodGoogle Scholar
- 15.Clarkson B, Gaynor J, Little C et al. (1990) Clinical trials in adults with acute lymphoblastic leukaemia at Memorial Sloan-Kettering Cancer Centre. Acute Lymphoblastic Leukaemia, Eds Gale & Hoelzer, 231–252Google Scholar